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ABSTRACT 
 
Indigenous populations, including Indigenous Australians, are highly susceptible to 
severe influenza disease and the underlying mechanisms are unknown. We studied 
immune correlates that predicate severe influenza disease in Indigenous Australians 
enrolled in the LIFT study: Looking into InFluenza T cell immunity. To examine CD8+ 
T cell immunity, we characterised human leukocyte antigen (HLA) profiles. HLA typing 
confirmed previous studies showing predominant usage of HLA-A*02:01, 11:01, 24:02, 
34:01 and HLA-B*13:01, 15:21, 40:01/02, 56:01/02 in Indigenous Australians. We 
identified two new HLA-A*02 and HLA-B*56 alleles (HLA-A*02:new and HLA-
B*56:new). Structural modelling suggests that variations within HLA-A*02:new (but not 
HLA-B56:new) may affect peptide binding. There is a relative lack of known influenza 
epitopes for the majority of the HLAs, with the exception of a universal HLA-A*02:01-
M158 epitope and proposed epitopes presented by HLA-A*11:01/HLA-A*24:02. To 
dissect universal CD8+ T cell responses, we analysed the magnitude, function and T cell 
receptor (TCR) clonality of HLA-A*02:01-M158+CD8+ T cells. We found comparable 
IFN-, TNF and CD107a and TCR characteristics in Indigenous and non-Indigenous 
Australians, suggesting that the ~15% of Indigenous people that express HLA-A*02:01 
have universal influenza-specific CD8+ T cell immunity. Furthermore, the frequency of 
an influenza host risk factor, IFITM3-C/C, was comparable between Indigenous 
Australians and Europeans, suggesting that expression this allele does not explain 
increased disease severity at a population level. Our study indicates a need to identify 
novel influenza-specific CD8+ T cell epitopes restricted by HLA-A and HLA-B alleles 
prevalent in Indigenous populations for the rational design of universal T cell vaccines.  
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INTRODUCTION 
 
Indigenous populations are at substantially higher risk of hospitalization and morbidity 
from influenza infection. Up to 10-20% of Indigenous Australians died from pandemic 
influenza in 1919 compared to <1% of non-Indigenous Australians 1. Similarly, although 
Indigenous Australians comprise 2.5% of the Australian population, they accounted for 
16% of patients hospitalised with pandemic (p) H1N1 and 9.7% of those admitted to ICU 
2
. Studies from the Northern Territory, Queensland and Western Australia have found 
that Indigenous Australians are 3-12 times more likely to be hospitalised than non-
Indigenous Australians. Similar patterns have been observed in Indigenous populations 
from New Zealand, Canada and the United States 3, 4, 5. Such great risk of hospitalization 
could reflect higher infection rates due to crowded living conditions, and also increased 
rates of chronic disease and comorbidities that lead to more severe outcome. In this 
setting, pre-emptive vaccination is clearly of significant benefit. However, prior 
administration of the currently available vaccines confers no protection against newly-
emerged unpredicted influenza viruses. Ultimately, the capacity to clear influenza virus 
and recover depends on the immune status of the individual.  
Immune factors, including host genetic factors, can lead to increased severity of 
influenza disease in some ethnicities. This is exemplified by the expression of an 
interferon-induced transmembrane protein 3 (IFITM3) SNP rs12252, with the IFITM3 
rs12252-C/C genotype (versus C/T or T/T) being predictive of early hypercytokinemia 
and severe influenza-induced disease. The IFITM3 C/C genotype is highly prevalent in 
the Asian population and correlates with severe pH1N1 and H7N9 disease 6, 7. The 
prevalence of the IFITM3-C/C genotype in Indigenous Australians has not yet been 
documented. 
Differences in influenza-specific T cell immunity, especially the protective CD8+ 
T cell responses 8, 9, 10, can be affected by distinct human leukocyte antigen (HLA) profiles  
(HLA restriction) found across different ethnicities 11. Our recent work showed that 
Indigenous populations, including Indigenous Australians and Alaskans, are at greater 
risk from severe influenza disease caused by newly-emerged influenza viruses due to a 
lack of CD8+ T cells directed at universal influenza epitopes 11. Thus, prolonged and more 
severe influenza infection in the Indigenous population might reflect differences in CD8+ 
T cell immunity associated with specific HLA profiles expressed. Indeed, the 
computational data suggest a strong correlation between pH1N1 influenza-induced 
mortality and the expression of HLA-A24 12, an allele highly prevalent in Indigenous 
Australians and Alaskans 13. Previous studies also suggest that some HLA molecules of 
Indigenous Australians differ from those that predominate in non-Indigenous Australians 
14, 15, 16
. Thus, HLAs expressed in Indigenous populations may bind different viral 
peptides and induce distinct CD8+ T cell responses in comparison to non-indigenous 
individuals. To date, there are no data on influenza-specific CD8+ T cell responses, in the 
context of HLA restriction, in Indigenous Australians. Given the recent emergence of 
new influenza viruses capable of infecting humans (H7N9, H6N5, H10N8), there is an 
urgent need to understand the immune correlates, and especially the effectiveness of 
CD8+ T cell immunity within the vulnerable Indigenous communities.  
Here, we studied influenza-specific CD8+ T-cells epitopes in a cohort of 
Indigenous Australians enrolled in the LIFT study: Looking into InFluenza T-cell 
immunity. Our HLA analysis verified previous reports of predominant usage of HLA-
A*02:01, 11:01, 24:02, 34:01 and HLA-B*13:01, 15:21, 40:01/02, 56:01/02 in 
Indigenous Australians, and identified two new HLA-A*02 and HLA-B*56 alleles. We 
showed a relative lack of known epitopes for these highly represented HLAs and analysed 
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the magnitude, quality and clonality of CD8+ T-cells directed at a universal HLA-
A*02:01-M158 epitope. We found comparable characteristics of HLA-A*02:01-
M158+CD8+ T-cells in Indigenous and non-Indigenous Australians. Further, we 
determined low population frequency of IFITM3-C/C alleles in Indigenous Australians. 
We propose that identification of novel immunodominant influenza-specific CD8+ T-cell 
epitopes restricted by HLA alleles prevalent in the Indigenous populations should be a 
priority for the rational design of new influenza vaccine strategies. 
 
 
 
RESULTS 
 
“Looking into InFluenza T cell Immunity” (LIFT) Cohort.  
We recruited 82 Australian Indigenous donors (LIFT01-LIFT083; Table S1) in Darwin, 
Northern Territory, Australia. Participants included Indigenous patients at the Royal 
Darwin Hospital admitted with non-influenza related diagnoses and healthy volunteers in 
the Darwin region. The study was explained to potential participants by Indigenous 
research staff with the use of culturally appropriate flipcharts and all participants provided 
written informed consent. The study was approved by the Human Research Ethics 
Committee (HREC) of the Northern Territory Department of Health and Menzies School 
of Health Research, and included review by the Aboriginal Ethics Sub-committee of the 
HREC. The median age of participants was 45 years (interquartile range [IQR] 30, 55) 
and 42 (52%) were male. 
 
Restricted HLA allele expression in Indigenous Australians from the Top End.  
Our analysis of 82 LIFT donors showed that HLA allele expression in Top End 
Indigenous Australians is relatively restricted for both HLA Class I (Figure 1) and Class 
II (Figure 2). LIFT donors expressed a more restricted range of HLA alleles compared to 
Australian Caucasians (Figure S1). The four main HLA-A alleles in LIFT Indigenous 
donors (HLA-A*02:01, 11:01, 24:02 and 34:01) accounted for 79% of HLA-A alleles, 
whilst the 4 main HLA-B alleles (HLA-B*13:01, 15:21, 40:01/02, 56:01/02) accounted 
for 47% of HLA-B alleles (Figure 1). The main HLA-C alleles were HLA-C*01:02, 
04:01/02, 07:02 and 15:02.  
 Similarly, expression of HLA Class II alleles was largely limited (Figure 2). The 
most dominant HLAs were HLA-DRB1*06:03, HLA-DPB*102:01, 04:01, 05:01 and 
HLA-DQB1*03:01, 04:02, 05:03 and 06:01. Our data are in accordance with previous 
reports 17. Overall, HLA distribution in our LIFT cohort was similar to those found in 
previous Indigenous cohorts from Cape York, Groote Eylandt, Kimberley and Yuendumu 
regions (NCBI dbMHC Anthropology Resources). Thus, there is strong HLA 
conservation between geographically distinct Indigenous groups that were unlikely to 
have had extensive interaction. 
 
New HLA-A*02 and HLA-B*56 alleles in Indigenous Australians.  
Molecular sequencing of donors LIFT026 and LIFT053 identified two new HLA alleles 
thus far unique to Indigenous Australians. In LIFT053, the new HLA-A*02 allele differed 
from HLA-A*02:35:01 at 4 nucleotide positions affecting 3 codons. The first nucleotide 
substitution occurs at codon 62 (GGG to CGG) and results in an amino acid (aa) change 
of glycine to arginine. The second and third nucleotide substitutions at codon 63 (GAG 
to AAC) result in an aa change from glutamic acid to asparagine. A change in a nucleotide 
at codon 90 (GCC to GAC) results in an aa change from alanine to aspartic acid. 
Sequencing was verified on two occasions by the analysis of two independent samples. 
Position 90 is located in one of the loops outside the antigen-binding cleft of the HLA 
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molecule, and therefore is unlikely to change the bound peptide repertoire of the new 
HLA-A*02 allele. On the other hand, positions 62 and 63 are located within the antigen 
binding cleft (Figure 3a), with position 62 exposed to the solvent and readily available 
for TCR contact, whereas position 63 is buried within the cleft and interacts with the 
residue at position 1 of the peptide. The larger arginine 62 of the new HLA-A*02 allele 
(Figure 3b) will most likely affect TCR interaction. In the HLA-A*02:35:01 molecule, 
the glutamic acid 63 makes a hydrogen bond with the main chain of the first residue of 
the peptide, stabilizing the bound peptide. In the new HLA-A*02 allele, the glutamic acid 
63 is replaced by an asparagine 63, which might not be as suited to strongly bind the 
position 1 of the peptide due to a smaller side chain (Figure 3c). The change at position 
63 might impact on peptide binding and change the peptide repertoire of the HLA-
A*02:new compared to that of the HLA-A*02:35:01 molecule. 
HLA-B*56:new was identified in donor LIFT026. This new allele differs from 
B*56:01:01G or B*56:02 at codon 75 (CGA to GGA) and results in an aa change from 
arginine to glycine. The arginine 75 of HLA-B*56:01 is located on the α1-helix of the 
cleft (Figure 3d), outside the cleft. This residue is unlikely to contact the TCR, therefore 
the change to glycine (Figure 3e) should not impact T cell recognition. The HLA residue 
75 does not contact the bound peptide, and the substitution from arginine to glycine 
(Figure 3f) is unlikely to impact the peptide repertoire. Therefore, the HLA-B*56:new 
and HLA-B*56:01 alleles should bind the same peptide repertoire. 
 
Dissection of influenza epitopes restricted by HLA-A and HLA-B alleles prevalent 
in Indigenous Australians. 
To understand the breadth of potential CD8+ T cell epitopes restricted by HLAs expressed 
in Indigenous Australians, we analysed epitopes corresponding to the immunogenic 
influenza proteins: nucleoprotein (NP), matrix 1 (M1) and polymerase basic 1 (PB1) 18, 
as outlined in the Immune Epitope Database (www.immuneepitope.org). We found that 
influenza-specific CD8+ T cell epitopes were previously proposed for four HLAs 
common to non-indigenous populations and identified within our LIFT cohort, including 
HLA-A*02:01 (40 epitopes), HLA-A*11:01 (20 epitopes), HLA-A*24:02 (10 epitopes) 
and HLA-B*40:02 (5 epitopes) (Table 1). In contrast, no influenza-specific epitopes have 
been identified for the remaining HLAs (HLA-A*02:new, HLA-A*15:25, HLA-
A*34:01, HLA-B*13:01, HLA-B*15:21, HLA-B*40:02, HLA-B*56:01, HLA-B*56:02, 
HLA-B*56:new) prominent in our LIFT cohort or described as distinct to Indigenous 
Australians (Table 1). Thus, no influenza-specific CD8+ T cell epitopes have been yet 
proposed for 71% of class I HLA alleles identified in Indigenous Australians. This 
suggests a need to identify prominent influenza epitopes restricted by HLAs associated 
with Indigenous populations in order to accurately determine the extent of CD8+ T cell 
immunity in this population. Furthermore, our findings suggest that the immunodominant 
epitopes in Indigenous Australians are likely to differ from dominant CD8+ T cell 
specificities in Caucasian populations. 
 
Universal CD8+ T cell immunity directed at the universal HLA-A*02:01-restricted 
M158-66 epitope. 
There are currently no data published on influenza-specific CD8+ T cell responses in the 
Indigenous Australian population. It is, however, well documented that HLA-A*02:01-
positive individuals generate prominent CD8+ T cell responses towards the viral M158-66 
peptide, highly
 
conserved amongst distinct influenza strains and subtypes 11, 19. To 
understand how robust and functional M158+CD8+ T cells are in the ~15% of Indigenous 
donors who express HLA-A*02:01, we analysed PBMCs from HLA-A*02:01-positive 
LIFT donors stimulated with the M158 peptide, a method used routinely to amplify 
influenza-specific memory CD8+ T cells 20, 21. M158+CD8+ T cell numbers and their 
 6 
functional capacities were assessed on d10 after the in vitro stimulation. Analysis of 7 
LIFT individuals of various ages revealed the presence of prominent M158+CD8+ T cell 
responses in 6 HLA-A*02:01 donors (LIFT07, LIFT09, LIFT011, LIFT022, LIFT027, 
LIFT029), but not LIFT03, who expressed HLA-A*02:05 (rather than HLA-A*02:01) 
positive (Figure 4a). Staining with the A2-M158 tetramer showed robust expansion of 
influenza-specific CD8+ T cells on d10 after in vitro stimulation (mean of 4.2% of CD8+ 
T cells; range 1.23% to 9.48%).  
We next determined the qualitative characteristics of M158+CD8+ T cells in the 
LIFT cohort. As high quality CD8+ T cells simultaneously produce multiple cytokines 
and display killing capacity, we assessed the production of IFN- and TNF together with 
CD107a degranulation following short-term stimulation (5hrs) with the M158 peptide and 
detection by an intracellular cytokine secretion (ICS) assay. Our data showed that 
M158+CD8+ T cells in the LIFT cohort were polyfunctional and 56.68%±16.3% produced 
both INF- and TNF (Figure 4b). A high proportion of those cells (66.8%±18.3%, 
representing 40.1±15.7% of all M158+CD8+ T cells) also expressed CD107a (Fig. 4C). 
 
Clonal characteristics of the universal CD8+ T cells directed at HLA-A*0201-
restricted M158-66 epitope. 
T cell receptor (TCR) usage plays an important role in determining the quality of the 
CD8+ T cell response to viruses and the outcome of infection 22, 23, 24, 25. Previous analyses 
of M158+CD8+ T cells, using mainly T cell clones, have described the M158-specific T 
cell receptor (TCR) repertoire as highly conserved 26, 27 and identified clones shared 
across different HLA-A*02:01+ individuals. Using in vitro cultures of three indigenous 
and three non-indigenous donors, we dissected the TCR repertoire utilised by M158+CD8+ 
T cells using a novel single-cell multiplex PCR for simultaneous amplification of the 
TCR and TCR chains (Figure 5)21, 28. The repertoires were compared in terms of TCR 
gene segment usage, CDR3 loop characteristics and clonal diversity. 
Similar to previous reports and our non-indigenous donors (Figure 5cd), HLA-
A*02:01-restricted M158+CD8+ T cells isolated from our LIFT cohort displayed a strong 
bias for TCR chain rearrangements that used the TRBV19 gene segment (frequency of 
94.49±2.11%) and a moderate bias for TRAV27 in the TCR chain (39.55±11.30%, 
Figure 5ab, Table 2). As seen in non-indigenous donors, individuals in the LIFT cohort 
also displayed a preference for TRBJ2-7 (41.96±18.14% of clones) and TRAJ42 
(54.53±12.59% of clones) and a predominant CDR3 length of 8 aa (80.21±9.02% of 
clones). SIRSSYEQ and GGSGQGNL were the most common TRBV19 and TRAV27 
CDR3 or  signatures, respectively, in accord with previous reports. Conversely, LIFT 
donors displayed a preference for CDR3 lengths of 7 aa (28.97±14.76% of clones), 9 aa 
(19.04±8.33% of clones) and 10 aa (19.99±9.27% of clones) in comparison to non-
indigenous individuals, which preferentially selected CDR3 loops of 9 aa in length 
(41.75±17.24 of clones), followed by 7 aa (28.46±18.88 of clones) and 10 aa 
(23.20±16.63 of clones). Whilst not significant, these trends suggest that M158+CD8+ 
TCR repertoires isolated from Indigenous donors may display a higher level of 
diversity than non-indigenous donors. This is evidenced by an increased number of 
unique CDR3 (18.33±2.31 versus 10.33±4.73 clonotypes) and CDR3 clones 
(15.67±2.52 versus 8±2.65 clonotypes) and CDR3 pairs (17.67±4.04 versus 
11.33±4.62 pairs) per donor, with an increase in Simpsons index of diversity (0.94±0.03 
versus 0.86±0.13 diversity).  
Overall, our data from Indigenous LIFT donors suggest that in HLA-A*02:01-
positive donors A2-M158-specific CD8+ T cells are numerically, functionally and clonally 
comparable to those providing universal immunity to distinct influenza strains and 
subtypes in non-Indigenous populations 11, 19, 29. 
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Similar pattern of Rs12252-IFITM3 distribution in Indigenous Australians and 
Europeans.  
Rs12252 in interferon-induced transmembrane protein 3 (IFITM3) can prevent 
endocytosed virus particles from entering the host cytoplasm and thus, to some extent, 
control the viral infection 6. The SNP rs12252-C variant (C/C genotype), on the other 
hand, leads to a 21 aa truncation of IFITM3 and is associated with severe outcome of viral 
diseases, including influenza A virus, HCV and VSV infections 6, 7, 30. High prevalence 
(30.1%) of rs12252-C/C in East Asia correlates with influenza disease severity 6, 7 and 
indicates that East Asian populations historically experienced different infection disease 
patterns from European people who have an rs12252-C/C frequency of <1% (Figure 6). 
Thus, it was of importance to understand the patterns of SNP rs12252 in Indigenous 
Australians. Our analysis of rs12252 distribution patterns in Indigenous people showed 
similar patterns in Europeans and Indigenous people (Figure 6), suggesting that IFITM3-
C/C genotype is an unlikely immune correlate for high influenza disease severity in 
Indigenous Australians. Furthermore, it is interesting that whilst our HLA results (Figures 
1-3) showed that Indigenous people share some similarity in HLA patterns with Asian 
populations, which suggests an ancestral link, the IFITM3 genotypes (Figure 6) are 
distinct. Considering that African Americans (AFR_AMR, 5.2%, C/C) have similar 
rs12252-C/C patterns to their ancestor Africans (AFR, 6.1%, C/C), it seems that mixing 
of AFR and European populations in America two centuries ago did not impose 
significant changes in rs12252-C/C distribution. Perhaps distinct disease burdens have 
selectively shaped rs12252-C/C distribution in Asian and Indigenous Australian 
populations, whilst similar HLA patterns have been retained. 
 
 
DISCUSSION  
Indigenous populations, including Indigenous Australians and Alaskans, are at high risk 
of severe influenza disease 11. In the case of an emergence of a new influenza viral strain, 
including avian-derived influenza viruses such as A/H7N9 9, CD8+ T cells can play an 
important role in host recovery. However, pre-existing influenza-specific CD8+ T cell 
responses recognizing distinct influenza strains and subtypes vary greatly across 
ethnicities 11 and HLA profiles. We found that while ~15% of Indigenous Australians 
(HLA-A*02:01-positive), would have robust universal CD8+ T cell pools, epitopes 
associated with other HLA types prominent in Indigenous people are unknown. 
 Our analysis of the LIFT cohort found that Indigenous Australians display a 
restricted and distinct HLA profile in accordance with previously published serological 
studies 14, 15, 16. Our molecular HLA typing verified the predominant usage of HLA-
A*02:01, 11:01, 24:02, 34:01 and HLA-B*13:01, 15:21, 40:01/02, 56:01/02. Such 
restriction in HLA diversity and HLA usage is likely to have arisen from an evolutionary 
bottle-neck that established a small ancestral pool with limited HLA diversity. As 
diversity of HLA alleles evolves rapidly, it is intriguing that there is a high degree of 
conservation in Indigenous Australians. This could be partly explained by limited mixing 
with other populations, long term adaptation to local pathogens, and minimal exposure to 
new pathogens that might drive selection and/or emergence of new variants. Limited or 
no exposure to influenza prior to European contact in the 18th century may explain a low 
prevalence of protective HLA variants for influenza. 
Additionally, we identified two new HLA alleles, HLA-A*02:new and HLA-
B*56:new, in 2 out of 82 LIFT donors. The amino acid changes in HLA-A*02:new could 
potentially impact the repertoire of bound epitopes. In HLA-A*02:01 the glutamic acid 
63 is buried in the cleft and interacts with the first residue of the peptide via a network of 
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hydrogen bonds. The asparagine 63 of the HLA-A*02:new will be too short to form the 
same network and will contact the peptide residue 1 via hydrophobic interaction only. In 
the case of a long side chain residue at position 1 of the peptide, more interactions with 
other HLA amino acids, namely tryptophan 167 and lysine 66, might be able to further 
stabilize the bound epitope. However, if the residue at position 1 has a small side chain 
or no side chain, such as the glycine of M158, the substituted asparagine 63 might have 
an impact on the stability of the peptide. Potentially, the HLA-A*02:new might not be 
able to bind, or not as stably, the M158 epitope compared to the HLA-A*02:01 molecule. 
Establishment of robust HLA-A*02:01-M158-specific CD8+ T cell responses with 
a typical magnitude, function and TCR repertoire structure in HLA-A*02:01-positive 
Indigenous Australians suggests that at least ~15% of Indigenous Australians would have 
cross-strain protective CD8+ T cell immunity. Once established, M158+CD8+ T cells can 
recognize any influenza strain and subtype due to the high level of conservation of this 
epitope 11, 19, 29. We thus provide the first data on influenza-specific T cell immunity in 
the Indigenous population. Our findings suggest that the distinct HLA profiles in 
Indigenous Australians do not affect CD8+ T cell responses to known, well-characterised 
influenza epitopes. However, the distinct HLAs found in Indigenous Australians may 
present a different set of viral peptides and thus induce unique CD8+ T cell responses in 
comparison to non-indigenous individuals. 
With the exception of HLA-A*02:01, little is known about the peptides presented 
by HLAs specific to Indigenous Australians (Table 1). Further studies are required to 
identify and characterize epitopes restricted by these unique HLA alleles, in particular 
HLA-A*34:01 (frequency of 24% of HLA-A alleles), HLA-B*13:01, 15:21, 56:01 and 
56:02 (together accounting for 43% of HLA-B alleles), to provide insights into the 
effectiveness of CD8+ T cell immunity in this population. Furthermore, as there is a strong 
correlation between the expression of HLA-A*24 and pH1N1 influenza-induced 
mortality 12, analyses of CD8+ T cell responses to epitopes restricted by HLA-A*24 
alleles in Indigenous Australians are a priority.  
Apart from HLA distribution, the expression of IFITM3-C/C SNP rs12252 
represents the only other host factor known to be associated with increased influenza 
disease severity across different ethnicities. Following influenza A virus infection, the 
expression of IFITM3-C/C SNP rs12252 is related to an early hypercytokinemia, 
especially in the Asian population 6, 7. The rs12252-C genotype is reasonably infrequent 
in Indigenous Australians, suggesting that compromised IFITM3 function is not linked 
to the increased susceptibility to severe influenza disease in this population.  
To support the rational design of an effective, broad-spectrum universal vaccine, 
it is essential to define the dominant influenza-specific T cell responses focused on the 
allelic HLA variants characteristic of Indigenous Australians 15, 16. 
 
 
 
METHODS 
 
Human ethics 
All the experiments conformed to the NHMRC Code of Practice and were approved by 
the University of Melbourne Research Human Ethics Committee (Applications 
#1441452.1 and #0931311.5) and the Human Research Ethics Committee of Northern 
Territory Department of Health and Menzies School of Health Research (Application # 
HREC-2012-1928). 
 
Recruitment of Indigenous Australian donors (LIFT cohort) 
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To understand influenza-specific responses in the Indigenous population, participants 18years of age were recruited from the Royal Darwin Hospital (RDH) and also from 
healthy volunteers in Darwin as a “Looking into InFluenza T cell Immunity” (LIFT) 
Cohort. We ensured representation of different age groups across the main regions of the 
Top End (Darwin urban, Darwin rural, West Arnhem/Daly, Tiwi Islands, East Arnhem, 
Katherine). This permitted sampling from a range of language and people groups so as 
not to bias the population HLA distribution. For hospital inpatients, permissions were 
requested from the treating clinical team for the research team to approach potential 
participants. Patients were then approached to discuss the study and seek informed 
consent for access to medical and immunisation records and to obtain a 50 ml venous 
blood sample. Participants were excluded if they had a diagnosis of Systemic 
Inflammatory Response (SIRS) (defined as satisfying ≥βSIRS criteria–temperature<36°C 
or >38°C; heart rate>90bpm; respiratory rate>20bpm; white blood cell count <4x109/L 
or >12x109/L) or a haemoglobin below the normal range. Participant recruitment, sample 
collection, isolation by Ficoll Paque density centrifugation (GE Healthcare, Australia) 20 
and storage of peripheral blood mononuclear cells (PBMCs) were performed at the 
Menzies School of Health Research. PBMCs were cryopreserved for further use at 
University of Melbourne. DNA was isolated from granulocytes using a QIAGEN 
QIAamp DNA Mini Kit according to manufacturer’s instructions.  
 
PBMC isolation from buffy packs 
PBMCs were isolated also from buffy packs (obtained from the Blood Bank in 
Melbourne, Australia) for HLA-A*02:01+ non-Indigenous donors. PBMCs were isolated 
by Ficoll Paque density centrifugation 20, then cryopreserved for future use.  
 
HLA typing and IFITM3 genotyping 
HLA class I and class II molecular genotyping was performed from genomic DNA by the 
Victorian Transplant and Immunogenetics Service (Parkville, Australia). For IFITM3 
sequencing, the exon 1 region of IFITM3 containing rs12252 was amplified from 
genomic DNA by PCR with forward (5′-GGAAACTGTTGAGAAACCGAA-γ′) and 
reverse (5′-CATACGCACCTTCACGGAGT-γ′) primers, as previously described 7.  
 
Generation of M158-specific CD8+ T cell lines 
To amplify influenza-specific CD8+ T cells directed at the immunodominant HLA-
A*02:01-restricted M158-66 epitope, PBMCs from HLA-A*02 donors were stimulated 
with the M158-66 (GILGFVFTL) peptide and then cultured for 10 to 19 days, as previously 
described 20, 31. Cultures were supplemented twice weekly with 10 U/mL rIL-2 and CD8+ 
T cell lines from non-indigenous donors were re-stimulated once weekly with gamma-
irradiated M158-pulsed C1R-A*02:01 cells. 
 
Intracellular cytokine staining (ICS)  
At d10, HLA-A*02-M158+CD8+ T cells from Indigenous donors were assessed by an 
IFN-Ȗ -A*02:01+ were used as antigen presenting cells 
(APCs) in an ICS assay to re-stimulate PBMCs. APCs (at 1-3x107 cells/ml) were pulsed 
with 10 µM peptide in 100 -free media RPMI for 60 mins at 37°C. Subsequently, 
1x105 peptide-pulsed APCs were co-cultured with 2x105 restimulated PBMC samples for 
5 hrs at 37°C in U-bottom 96-well plates in the presence of IL-2 (10 U/ml), 2 μL 
GolgiPlug (BD Biosciences, final dilution of 1:1000) and 1.33 μL Golgi-Stop (BD 
Biosciences,final dilution of 1:1500) and 1 μ anti-CD107a-AF700 (eBiosceinces). 
Following stimulation, cells were washed with FACS buffer (1% BSA (Gibco) and 0.02% 
sodium azide (Sigma) in PBS) and stained with anti-CD3-PeCy7 (eBiosceinces) and anti-
CD8-PerCP-Cy5.5 (BD Biosciences) and Live/Dead-NIR (Invitrogen) in PBS, and then 
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washed twice. Cells were fixed and permeabilised using the BD Cytofix/Cytoperm Plus 
Fixation/Permeabilisation Kit (BD Biosciences), and intracellularly-stained with anti-
IFN--V450 (BD Horizon), anti-TNF-APC (BD Biosceinces) in perm-wash buffer. 
Samples were washed and acquired by flow cytometry on a BD FACS Canto II (BD 
Biosciences) and analysed by FlowJo software (Treestar). Cytokine production was 
calculated by subtracting background fluorescence using ‘no peptide’ C1R-A*02:01+ 
controls.  
 
Tetramer staining  
D10-19 M158 cultures were stained with HLA-A*02:01-M158 tetramer conjugated to PE 
at a 1:100 dilution in FACS buffer (PBS with 0.1% BSA) or PBS. Cells were then washed 
twice with cold FACS buffer and stained with a cocktail of antibodies including anti-
CD3-PB (Biolegend) or anti-CD3-PeCy7 (eBiosciences), anti-CD8-PerCPCy5.5 or anti-
CD8-PerCP (both BD Biosciences), CD27-APC (BD Biosciences), CD45RA-FITC (BD 
Pharmingen) and Live/Dear-NIR (Invitrogen) (Indigenous donors only), washed twice 
with FACS buffer or PBS. Cells were then resuspended in 200 μl of sort buffer and passed 
though a 45 nm sieve prior to flow cytometric analysis or sorting.  
 
Single-cell multiplex RT-PCR for paired CDR3 and CDR3 analysis 
CD8+ T cell lines were tetramer-stained as above and single HLA-A*02:01-M158-
tetramer+ CD3+dump-CD8+tetramer+ cells were single-cell sorted on a FACS Aria III (BD 
Biosciences) into 80 wells of a 96 well twin-tec plate (Eppendorf). The CDR3αȕ regions 
were determined by a novel single cell multiplex RT-PCR protocol 21, 28. mRNA 
transcripts were reverse-transcribed to cDNA, using a VILO kit (Invitrogen, CA, USA). 
For the internal round of PCR, 2.5 µl of the external product was used as template, with 
either a set of TRAV or TRBV internal primers 28. The internal PCR reaction included 
the 2 different primers sets at 5 pmol/ml (TRAV and TRAC, or TRBV and TRBC). 
Positive PCR products were purified with Exo-SAP-IT (Affymetrix) and sequenced using 
TRAC or TRBC internal primers with BigDye v3.1 (Applied biosciences). Sequences 
were cleaned using DyeEx sequencing plates (QIAGEN) and sequencing was performed 
at the Sequencing and Genotyping facility within the Department of Pathology at the 
University of Melbourne. Sequences were analysed using FinchTV, and V and J region 
usage was identified by IMGT query (www.imgt.org/IMGT_vquest).  
 
New HLA class I modeling 
The HLA-A*02:new model was made using the published HLA-A*02:01 structure (PDB 
code: 3GSO 20) and mutating the corresponding residues: glycine 62 to arginine, glutamic 
acid 63 to asparagine. The HLA-B*56:new was modeled using the HLA-B*57:01 
structure (PDB code: 3VRI {Illing, 2012 #16}) and mutating the residue 75 from arginine 
to glycine. All the mutations have been generated in Pymol 32. 
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FIGURE LEGENDS 
 
Figure 1. HLA class I allele expression in Indigenous Australians from the Top End. 
DNA typing of HLA-A, -B and -C alleles was performed for 82 Indigenous Australian 
individuals from the Top End of the Northern Territory in Australia (LIFT cohort; 
2n=164). The range and frequency of HLA class I allele expression are shown compared 
against previous studies of HLA class I expression in Indigenous Australians obtained 
from NCBI dbMHC Anthropology Resources (available online at 
www.ncbi.nlm.nih.gov/gv/mhc/ihwg.cgi?cmd=page&page=AnthroMain) (HLA-A, 
2n=810; HLA-B, 2n=812; HLA-C, 2n=764). 
 
Figure 2. HLA class II allele expression in Indigenous Australians from the Top End. 
DNA typing of HLA-DRB1, -DPB1 and -DQB1 was performed for Indigenous 
Australian individuals (LIFT cohort; 2n=164). Allele expression is shown as described in 
Fig. 1. Data from NCBI dbMHC Anthropology Resources represents: HLA-DRB1, 
2n=280; HLA-DPB1, 2n=268; HLA-DQB1, 2n=280. 
 
Figure 3. Modeling of new HLA class I alleles identified in Top End Indigenous 
Australians. The top panels show (a) the HLA-A*02:01 cleft, (b) HLA-A*02:new and 
(c) a superposition of both HLAs. The HLA cleft is represented in cartoon and the key 
residues as stick, coloured in white for HLA-A*02:01 and pink for HLA-A*02:new. The 
dashed lines represent the interaction between the HLA residue 63 and the peptide residue 
1. The bottom panels represent the (d) HLA-B*56:01 in grey, (e) HLA-B*56:new in cyan 
and (f) a superposition of both HLAs. The sphere represents the Cα atom of the glycine 
75.  
 
Figure 4. Establishment of robust A2-M158-specific CD8+ T cell responses in A*02+ 
Indigenous Australians. A2-M158-specific CD8+ T cell lines were generated by pulsing 
PBMCs from A*02+ donors with M158-66 peptide for 10 days in the presence of rIL-2. 
Plots (a) show A2-M158 tetramer-PE and anti-CD8-PerCPCy5.5 staining of CD3+ T cells. 
Values in parenthesis indicate the proportion of CD8+ T cells that bound A2-M158 
tetramer. The function of A2-M158-specific CD8+ T cells was assessed following peptide 
stimulation in an ICS assay examining expression of IFN-, TNF and CD107a (b, c). 
Plots (b) show anti-IFN--V450 and anti-TNF-APC staining of CD3+CD8+ T cells. The 
polyfunctional profile of M158-specific CD8+ T cells is compared in (c). 
 
Figure 5. A2-M158-specific CD8+ T cells from Indigenous Australians display 
characteristic TCR repertoire usage. Single A2-M158-specific CD8+ T cells from 
(a, b) three representative Indigenous and (c, d) three representative non-Indigenous 
donors were sorted from day 10-19 in vitro cultures for analysis of the TCR repertoire 
using a multiplex PCR and sequencing protocol. (a, c) TRBV and TRAV gene usage was 
compared across donors and (b, d) clonotype usage with the prominent BV19/AV27+ 
subset was further dissected to reveal common usage of a well-defined public A2-M158-
specific TCR clonotype. 
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Figure 6. Expression of IFITM3 genotype associated with increased influenza 
disease severity across different ethnicities. Sequencing of the exon 1 region of IFITM3 
containing rs12252 was performed for Indigenous Australians to determine allele 
frequencies of the SNP rs12252-C variant (in contrast to the WT rs12252-T variant) 
associated with increased influenza disease severity. Occurrence of the C/C, T/C and T/T 
genotypes was determined for this study population and compared with data for other 
ethnicities obtained from the 1000 genomes project (available on line at 
www.1000genomes.org). 
 
 
REFERENCES 
 
1. Briscoe G. Disease Health & Healing – Aspects of Indigenous Health in WA & 
Queensland, 1900-1940. PhD thesis 1996. 
 
2. Flint SM, Davis JS, Su JY, Oliver-Landry EP, Rogers BA, Goldstein A, et al. 
Disproportionate impact of pandemic (H1N1) 2009 influenza on Indigenous 
people in the Top End of Australia's Northern Territory. Med J Aust 2010, 
192(10): 617-622. 
 
3. Investigators AI, Webb SA, Pettila V, Seppelt I, Bellomo R, Bailey M, et al. 
Critical care services and 2009 H1N1 influenza in Australia and New Zealand. 
N Engl J Med 2009, 361(20): 1925-1934. 
 
4. La Ruche G, Tarantola A, Barboza P, Vaillant L, Gueguen J, Gastellu-
Etchegorry M, et al. The 2009 pandemic H1N1 influenza and indigenous 
populations of the Americas and the Pacific. Euro Surveill 2009, 14(42). 
 
5. Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, et al. Critically 
ill patients with 2009 influenza A(H1N1) infection in Canada. Jama 2009, 
302(17): 1872-1879. 
 
6. Zhang YH, Zhao Y, Li N, Peng YC, Giannoulatou E, Jin RH, et al. Interferon-
induced transmembrane protein-3 genetic variant rs12252-C is associated 
with severe influenza in Chinese individuals. Nat Commun 2013, 4: 1418. 
 
7. Wang Z, Zhang A, Wan Y, Liu X, Qiu C, Xi X, et al. Early hypercytokinemia is 
associated with interferon-induced transmembrane protein-3 dysfunction 
and predictive of fatal H7N9 infection. Proc Natl Acad Sci U S A 2014, 111(2): 
769-774. 
 
8. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, et 
al. Cellular immune correlates of protection against symptomatic pandemic 
influenza. Nat Med 2013, 19 1305-1312. 
 
9. Wang Z, Wan Y, Qiu C, Quinones-Parra S, Zhu Z, Loh L, et al. Recovery from 
severe H7N9 disease is associated with diverse response mechanisms 
dominated by CD8(+) T cells. Nat Commun 2015, 6: 6833. 
 
10. Hayward AC, Wang L, Goonetilleke N, Fragaszy EB, Bermingham A, Copas A, 
et al. Natural T Cell-mediated Protection against Seasonal and Pandemic 
 13 
Influenza. Results of the Flu Watch Cohort Study. Am J Respir Crit Care Med 
2015, 191(12): 1422-1431. 
 
11. Quinones-Parra S, Grant E, Loh L, Nguyen TH, Campbell KA, Tong SY, et al. 
Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across 
ethnicities. Proceedings of the National Academy of Sciences of the United 
States of America 2014, 111(3): 1049-1054. 
 
12. Hertz T, Oshansky CM, Roddam PL, DeVincenzo JP, Caniza MA, Jojic N, et al. 
HLA targeting efficiency correlates with human T-cell response magnitude 
and with mortality from influenza A infection. Proceedings of the National 
Academy of Sciences of the United States of America 2013, 110(33): 13492-
13497. 
 
13. Ahmed R, Oldstone MB, Palese P. Protective immunity and susceptibility to 
infectious diseases: lessons from the 1918 influenza pandemic. Nature 
immunology 2007, 8(11): 1188-1193. 
 
14. Lester S, Cassidy S, Humphreys I, Bennett G, Hurley CK, Boettcher B, et al. 
Evolution in HLA-DRB1 and major histocompatibility complex class II 
haplotypes of Australian aborigines. Definition of a new DRB1 allele and 
distribution of DRB1 gene frequencies. Hum Immunol 1995, 42(2): 154-160. 
 
15. Lienert K, McCluskey J, Bennett G, Fowler C, Russ G. HLA class I variation in 
Australian aborigines: characterization of allele B*1521. Tissue Antigens 
1995, 45(1): 12-17. 
 
16. Gao X, Lester S, Matheson B, Boettcher B, McCluskey J. Three newly identified 
A*24 alleles: A*2406, A*2413 and A*2414. Tissue Antigens 1997, 50(2): 192-
196. 
 
17. Lin L, Tokunaga K, Tanaka H, Nakajima F, Imanishi T, Kashiwase K, et al. 
Further molecular diversity in the HLA-B15 group. Tissue Antigens 1996, 
47(4): 265-274. 
 
18. Lee LY, Ha do LA, Simmons C, de Jong MD, Chau NV, Schumacher R, et al. 
Memory T cells established by seasonal human influenza A infection cross-
react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 2008, 
118(10): 3478-3490. 
 
19. van de Sandt CE, Kreijtz JH, de Mutsert G, Geelhoed-Mieras MM, Hillaire ML, 
Vogelzang-van Trierum SE, et al. Human cytotoxic T lymphocytes directed to 
seasonal influenza A viruses cross-react with the newly emerging H7N9 
virus. Journal of virology 2014, 88(3): 1684-1693. 
 
20. Gras S, Kedzierski L, Valkenburg SA, Laurie K, Liu YC, Denholm JT, et al. Cross-
reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and 
H1N1-1918 influenza A viruses. Proc Natl Acad Sci U S A 2010, 107: 12599-
12604. 
 
 14 
21. Nguyen TH, Rowntree LC, Pellicci DG, Bird NL, Handel A, Kjer-Nielsen L, et al. 
Recognition of distinct cross-reactive virus-specific CD8+ T cells reveals a 
unique TCR signature in a clinical setting. Journal of immunology 2014, 
192(11): 5039-5049. 
 
22. Messaoudi I, Guevara Patino JA, Dyall R, LeMaoult J, Nikolich-Zugich J. Direct 
link between mhc polymorphism, T cell avidity, and diversity in immune 
defense. Science 2002, 298(5599): 1797-1800. 
 
23. Price DA, West SM, Betts MR, Ruff LE, Brenchley JM, Ambrozak DR, et al. T 
cell receptor recognition motifs govern immune escape patterns in acute SIV 
infection. Immunity 2004, 21(6): 793-803. 
 
24. Valkenburg SA, Day EB, Swan NG, Croom HA, Carbone FR, Doherty PC, et al. 
Fixing an irrelevant TCR alpha chain reveals the importance of TCR beta 
diversity for optimal TCR alpha beta pairing and function of virus-specific 
CD8+ T cells. European journal of immunology 2010, 40(9): 2470-2481. 
 
25. Valkenburg SA, Gras S, Guillonneau C, La Gruta NL, Thomas PG, Purcell AW, 
et al. Protective efficacy of cross-reactive CD8+ T cells recognising mutant 
viral epitopes depends on peptide-MHC-I structural interactions and T cell 
activation threshold. PLoS pathogens 2010, 6(8): e1001039. 
 
26. Lehner PJ, Wang EC, Moss PA, Williams S, Platt K, Friedman SM, et al. Human 
HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is 
dominated by T cells bearing the V beta 17 gene segment. J Exp Med 1995, 
181(1): 79-91. 
 
27. Moss PA, Moots RJ, Rosenberg WM, Rowland-Jones SJ, Bodmer HC, 
McMichael AJ, et al. Extensive conservation of alpha and beta chains of the 
human T-cell antigen receptor recognizing HLA-A2 and influenza A matrix 
peptide. Proc Natl Acad Sci U S A 1991, 88(20): 8987-8990. 
 
28. Wang GC, Dash P, McCullers JA, Doherty PC, Thomas PG. T cell receptor 
alphabeta diversity inversely correlates with pathogen-specific antibody 
levels in human cytomegalovirus infection. Sci Transl Med 2012, 4(128): 
128ra142. 
 
29. Quinones-Parra S, Loh L, Brown LE, Kedzierska K, Valkenburg SA. Universal 
immunity to influenza must outwit immune evasion. Front Microbiol 2014, 5: 
285. 
 
30. Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, et al. IFITM3 restricts 
the morbidity and mortality associated with influenza. Nature 2012, 
484(7395): 519-523. 
 
31. Valkenburg SA, Rutigliano JA, Ellebedy AH, Doherty PC, Thomas PG, 
Kedzierska K. Immunity to seasonal and pandemic influenza A viruses. 
Microbes and infection 2011, 13(5): 489-501. 
 
 15 
32. DeLano WL. The PyMOL Molecular Graphics System. http://www. pymol.org.  
2002  [cited]Available from: http://www. pymol.org 
 
 
